Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


caobin_ben@163.com

Bin Cao

Professor of Respiratory Medicine

  • Professor, China-Japan Friendship Hospital
  • Vice President, China-Japan Friendship Hospital
  • Vice Director, Institute of Respiratory Medicine, China-Japan Friendship Hospital

As a physician-scientist, Dr. Cao is a leader of respiratory medicine, and a tireless researcher of evidence-based medicine for respiratory infections. Dr. Cao has founded the China Pneumonia Research Platform in China. He determined the incidence of community-acquired pneumonia (CAP) in China, with viral infection as high as 39.2%. His research promoted viral pneumonia to be written into the Chinese CAP guideline. He firstly revealed the clinical features of hospitalized COVID-19 cases, proposing a global pandemic warning, and found mortality risks for COVID-19. He studied the immune damage mechanism of severe influenza pneumonia, and pioneered the original concept of "viral sepsis" in severe viral pneumonia. He took the lead in standardizing low-dose corticosteroids therapy for severe and critically ill COVID-19 patients , leading to the innovation of clinical treatment of severe viral pneumonia. He led the world's first clinical trial for COVID-19, which proved the feasibility to conduct randomized controlled clinical trials in a pandemic. In an editorial, NEJM’s editor-in-chief comments Dr. Cao' work as an heroic effort. As a representative of China, he took part in the World Health Organization (WHO) R&D blueprints for COVID-19. Dr. Cao has lead the Long COVID study in China and characterized the common symptoms, quality of life, lung function and chest CT as well as the risk factors.